8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology.
The occurrence of pediatric cancer in children born from assisted reproductive technologies has been sporadically reported. Chromosomal characterization of the neoplasic disease in this setting is poorly described. In the present study, neuroblastoma cells from a 13-month-old infant boy born after intracytoplasmatic sperm injection were characterized by combining conventional cytogenetics, fluorescence in situ hybridization (FISH), comparative genomic hybridization, and quantitative polymerase chain reaction methods. Cytogenetic analysis of neuroblastoma (NB) metaphase spreads at the time of diagnosis revealed numerous centromere-free extrachromosomal double minutes, suggesting high MYCN amplification. Comparative genomic hybridization analysis demonstrated the amplification of 2q24 approximately pter, with additional gain of the long arm of chromosome 17. Chromosome losses involved 8q, 9q, and 11q. No deletion of 1p was found. MYCN amplification was confirmed by quantitative polymerase chain reaction and fluorescence in situ hybridization analysis. This report describes several chromosomal abnormalities that were present in NB of a child born after intracytoplasmatic sperm injection. Besides some well described and prognostic genetic findings in NB as MYCN amplification, gain on 17q and losses on 9q and 11q23, we report an unusual deletion involving 8q region in this disease. Whether this genetic abnormality may be associated to assisted reproductive technologies deserves further investigation.
Brassesco
María Sol
MS
Division of Pediatric Oncology, Department of Pediatrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, SP, Brazil. marsol@rge.fmrp.usp.br
Valera
Elvis Terci
ET
de Oliveira
Fabio Morato
FM
de Paula Queiroz
Rosane Gomes
RG
Scrideli
Carlos Alberto
CA
Sakamoto-Hojo
Elza Tiemi
ET
Tone
Luiz Gonzaga
LG
D000008:Abdominal Neoplasms / Q000235:genetics* / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D000071447:N-Myc Proto-Oncogene Protein; D009447:Neuroblastoma / Q000235:genetics* / Q000473:pathology; D009687:Nuclear Proteins / Q000235:genetics*; D015513:Oncogene Proteins / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020554:Sperm Injections, Intracytoplasmic / Q000009:adverse effects*
C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins